Shipping to Germany We Offer Worldwide Shipping
Login Wishlist

Solanidiene

$3,600

  • Brand : BIOFRON

  • Catalogue Number : BN-O1849

  • Specification : 98%(HPLC)

  • CAS number : 26516-51-8

  • Formula : C27H41N

  • Molecular Weight : 379.6

  • PUBCHEM ID : 101235373

  • Volume : 20mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1849

Analysis Method

Specification

98%(HPLC)

Storage

2-8°C

Molecular Weight

379.6

Appearance

Botanical Source

Structure Type

Category

SMILES

Synonyms

IUPAC Name

(1S,2S,10R,11S,14S,15R,16S,17R,20S,23S)-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.02,11.05,10.015,23.017,22]tetracosa-4,6-diene

Applications

Density

Solubility

Flash Point

Boiling Point

Melting Point

InChl

InChl Key

MVUKDQDMGIMFPT-LTLBHDAASA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:26516-51-8) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

31843919

Abstract

antimicrobial peptides, multidrug resistance, nosocomial infections, inflammation

KEYWORDS

antimicrobial peptides, multidrug resistance, nosocomial infections, inflammation

Title

The antimicrobial peptide ZY4 combats multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii infection

Author

James Mwangi,a,b,c,d,1 Yizhu Yin,a,b,c,1 Gan Wang,a,b,1 Min Yang,a,b,c,1 Ya Li,e Zhiye Zhang,a,b,2 and Ren Laia,b,d,f,g,h,2

Publish date

2019 Dec 26;

PMID

27049921

Abstract

The lack of efficient tumor progression and chemoresistance indicators leads to high mortality in epithelial ovarian cancer (EOC) patients. Dysregulated miR-520g expression is involved in these processes in hepatic and colorectal cancers. In this study, we found that miR-520g expression gradually increased across normal, benign, borderline and EOC tissues. High miR-520g expression promoted tumor progression and chemoresistance to platinum-based chemotherapy, and reduced survival in EOC patients. miR-520g upregulation increased EOC cell proliferation, induced cell cycle transition and promoted cell invasion, while miR-520g downregulation inhibited tumor-related functions. In vivo, overexpression or downregulation of miR-520g respectively generated larger or smaller subcutaneous xenografts in nude mice. Death-associated protein kinase 2 (DAPK2) was a direct target of miR-520g. In 116 EOC tissue samples, miR-520g expression was significantly lower following DAPK2 overexpression. DAPK2 overexpression or miR-520g knockdown reduced EOC cell proliferation, invasion, wound healing and chemoresistance. This study suggests that miR-520g contributes to tumor progression and drug resistance by post-transcriptionally downregulating DAPK2, and that miR-520g may be a valuable therapeutic target in patients with EOC.

KEYWORDS

miR-520g, epithelial ovarian cancer, progression, chemoresistance, DAPK2

Title

MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression

Author

Jing Zhang,#1 Lei Liu,#2 Yunyan Sun,1 Jiandong Xiang,1 Dongmei Zhou,1 Li Wang,1 Huali Xu,1 Xiaoming Yang,1 Na Du,1 Meng Zhang,3 Qin Yan,1 and Xiaowei Xi1

Publish date

2016 May 3

PMID

16390354

Abstract

Aims
Previous studies have demonstrated that the antihistamines mequitazine, cetirizine and dexchlorpheniramine produce mild sedation after single doses. It is unknown, however, whether acute sedation persists after repeated dosing. Therefore, this study assessed the effects of repeated dosing of these antihistamines on driving and psychomotor performance.

Methods
Sixteen healthy volunteers were treated with mequitazine 10 mg q.a.m., cetirizine 10 mg q.a.m., dexchlorpheniramine Repetab 6 mg b.i.d. and placebo for four separate 8-day periods. Drug effects were assessed on days 1 and 8 using on-the-road driving tests (highway driving and car following), psychomotor tests (tracking and divided attention) and subjective questionnaires.

Results
Dexchlorpheniramine and mequitazine significantly impaired driving performance on the highway driving test on the first day; dexchlorpheniramine increased Standard Deviation of Lateral Position by 2 cm [95% confidence interval (CI) 0.5, 3.8] and mequitazine by 2.5 cm (CI 1.0, 4.3). These effects on driving performance disappeared after 8 days of treatment. No effect of treatment was found on car following, tracking and divided attention. Although subjective ratings confirmed that subjects knew their driving had been impaired in the mequitazine and dexchlorpheniramine condition after completion of the highway driving test on day 1, they did not expect their driving to be affected before the start of the test. Cetirizine did not impair performance on any of the tests.

Conclusions
Single doses of mequitazine 10 mg and dexchlorpheniramine Repetab 6 mg cause mild driving impairment. However, when taken over several days, the impairing effect wears off, possibly as a result of tolerance.

KEYWORDS

antihistamine, cetirizine, driving, mequitazine, psychomotor performance, repeated-dose

Title

Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance

Author

Eef L Theunissen, Annemiek Vermeeren, and Johannes G Ramaekers

Publish date

2006 Jan;